Historical Context, Paradigm Shift, and Emergence of Immunothrombosis as a Central Framework
John Murphy, M.D, M.P.H., D.P.H. President Covid-19 Long-haul Foundation
Abstract
Post–acute sequelae of SARS-CoV-2 infection (PASC), commonly termed Long COVID, has been increasingly associated with persistent abnormalities in coagulation biology, including the proposed presence of circulating microclots resistant to fibrinolysis. While early pandemic research focused on acute thromboembolic disease in severe COVID-19, subsequent investigations have suggested that subtler and more persistent abnormalities in clot formation, fibrin architecture, platelet activation, and endothelial function may persist long after viral clearance.
This review traces the evolution of coagulation science in COVID-19 from classical thrombosis models to modern immunothrombotic frameworks, with particular emphasis on the emergence of microclot hypotheses in Long COVID. It evaluates how advances in platelet biology, fibrin biophysics, endothelial glycocalyx research, and neutrophil extracellular trap (NET) biology have collectively reshaped understanding of post-viral vascular dysfunction.
1. Introduction: From Respiratory Virus to Vascular Disease Paradigm
Early in the COVID-19 pandemic, SARS-CoV-2 was conceptualized primarily as a respiratory pathogen. However, by mid-2020, clinical observations rapidly challenged this narrow framing. Patients with severe infection exhibited disproportionate rates of:
- venous thromboembolism
- pulmonary microvascular obstruction
- stroke in younger individuals
- disseminated intravascular coagulation–like states
- endothelial injury markers
These findings forced a conceptual expansion of COVID-19 into a vascular and endothelial disease as much as a respiratory infection.
This shift laid the groundwork for later hypotheses that post-acute disease may also involve persistent vascular dysregulation, even after viral clearance.
2. Classical Coagulation Theory vs Immunothrombosis
Traditional coagulation biology was historically centered on a three-part cascade:
- intrinsic pathway activation
- extrinsic pathway activation
- fibrin clot formation and resolution
However, this model proved insufficient to explain the complexity of COVID-19-associated thrombosis.
A more comprehensive framework—immunothrombosis—emerged, integrating:
- innate immune activation
- endothelial signaling
- platelet immune function
- neutrophil extracellular traps (NETs)
- complement activation
In this model, coagulation is not merely a hemostatic process but a host defense mechanism that becomes pathologic under sustained inflammatory stimulation.
3. Endothelial Injury as the Central Initiating Event
One of the most significant conceptual advances in COVID-19 coagulation research was recognition of the endothelium as an active immunologic organ.
SARS-CoV-2 infection induces:
- endothelial activation
- glycocalyx degradation
- increased vascular permeability
- expression of adhesion molecules (ICAM-1, VCAM-1)
This endothelial perturbation creates a pro-thrombotic microenvironment characterized by:
- platelet adhesion
- leukocyte recruitment
- fibrin deposition
- impaired fibrinolysis
Importantly, endothelial dysfunction may persist beyond acute infection in subsets of patients, providing a mechanistic basis for chronic vascular abnormalities observed in Long COVID.
4. Emergence of Fibrin Structural Abnormalities
A key advance in coagulation science was the recognition that not all fibrin clots are structurally equivalent.
Under inflammatory conditions, fibrin can adopt:
- denser fiber networks
- altered branching architecture
- increased resistance to plasmin-mediated degradation
These structural changes result in clots that are:
- more persistent
- less susceptible to fibrinolysis
- more prone to microvascular obstruction
This shift in understanding moved the field from a purely quantitative coagulation model (clot presence/absence) to a qualitative structural fibrin model.
5. Microclots: Definition and Scientific Origins
The concept of “microclots” refers to:
submicron to micron-scale fibrin-rich aggregates that circulate in plasma and may resist normal fibrinolytic degradation.
In Long COVID research, microclots have been proposed as a potential mechanism for:
- impaired oxygen delivery
- exertional intolerance
- cognitive dysfunction
- vascular dysregulation
While definitions vary across laboratories, the central hypothesis is that these structures represent pathological fibrin assemblies that persist beyond acute infection.
6. Platelet Hyperactivation and Persistent Prothrombotic State
Platelets are increasingly recognized not only as hemostatic elements but as immune effector cells.
In COVID-19 and post-COVID states, platelets may exhibit:
- hyperreactivity
- increased aggregation tendency
- heightened P-selectin expression
- inflammatory cytokine release capacity
This dual hemostatic-immune role places platelets at the center of immunothrombotic pathology.
Persistent platelet activation has been proposed as one contributor to ongoing microvascular dysfunction in Long COVID, even in the absence of overt thrombosis.
7. NETosis and Fibrin Stabilization
Neutrophil extracellular traps (NETs) represent another major advancement in coagulation biology.
NETs consist of:
- extracellular DNA scaffolds
- histones
- proteolytic enzymes
They serve antimicrobial functions but also promote thrombosis by:
- activating coagulation cascades
- stabilizing fibrin networks
- inhibiting fibrinolysis
In COVID-19, excessive NET formation has been documented and is believed to contribute to both acute and potentially post-acute vascular dysfunction.
8. Complement Activation and Thromboinflammatory Feedback Loops
Complement activation further amplifies coagulation dysregulation.
Key components include:
- C3a and C5a anaphylatoxins
- membrane attack complex formation
- endothelial activation signaling
Complement-coagulation crosstalk creates a self-reinforcing thromboinflammatory loop, in which:
- immune activation triggers coagulation
- coagulation amplifies inflammation
- inflammation further enhances clot formation
This loop is particularly relevant to persistent post-viral vascular dysfunction.
9. Transition to Post-Acute Coagulation Research
While early COVID-19 research focused on acute thrombosis, a major shift occurred between 2021–2023 toward post-acute vascular abnormalities.
Key observations included:
- persistent endothelial activation markers
- elevated fibrin-related biomarkers in subsets of recovered patients
- prolonged platelet activation profiles
- microvascular dysfunction symptoms without overt thrombosis
These findings suggested that coagulation abnormalities may not fully resolve after infection in all individuals.
10. Conceptual Shift: From Thrombosis to “Vascular Dysregulation Syndrome”
The accumulation of evidence has led to a broader conceptual reframing:
Old model:
- COVID-19 causes acute clotting events only
New model:
- COVID-19 may trigger a persistent vascular dysregulation state in a subset of patients
This includes:
- endothelial dysfunction
- platelet hyperreactivity
- fibrin structural abnormalities
- microvascular flow impairment
Within this framework, microclots are not isolated phenomena but part of a broader post-thromboinflammatory continuum.
11. Relevance to Long COVID Symptomatology
The proposed microvascular dysfunction framework provides potential mechanistic links to common Long COVID symptoms:
| Symptom | Proposed vascular link |
|---|---|
| Fatigue | impaired tissue oxygen delivery |
| Brain fog | cerebral microvascular dysregulation |
| Exercise intolerance | oxygen extraction impairment |
| Palpitations | autonomic-vascular mismatch |
| Post-exertional malaise | metabolic-vascular insufficiency |
While causal relationships remain under investigation, the overlap between vascular dysfunction and symptom clusters is notable.
Conclusion (Part I)
The evolution of coagulation research in COVID-19 reflects a broader paradigm shift in biomedical science—from linear cascade models of thrombosis to complex immunothrombotic and endothelial-immune interaction systems. Within this framework, microclots in Long COVID represent a hypothesis situated at the intersection of fibrin biophysics, platelet immunology, and endothelial dysfunction.
Rather than a singular pathological entity, microclots are increasingly understood as a potential manifestation of persistent thromboinflammatory dysregulation following viral infection.
Clinical Translation, Therapeutic Trials, Controversies, and Integrated Disease Model
22. Clinical Translation: From Structural Observations to Therapeutic Hypotheses
The emergence of microclot-related findings in post–acute sequelae of SARS-CoV-2 infection (PASC) has prompted renewed interest in whether coagulation-targeted therapies might ameliorate persistent symptoms such as fatigue, exercise intolerance, and cognitive dysfunction.
However, the translation from in vitro fibrin observations to in vivo therapeutic intervention remains scientifically and clinically complex. Unlike classical thrombotic disease—where clot presence is radiologically or biochemically evident—Long COVID-associated coagulation abnormalities are often:
- subclinical
- microvascular in scale
- inconsistently detectable with standard assays
- intertwined with immune and endothelial dysfunction
This complicates therapeutic decision-making and trial design.
23. Anticoagulation Trials in Post-COVID States
Several exploratory studies and observational reports have investigated anticoagulant or antiplatelet strategies in post-COVID syndromes.
Investigated therapeutic classes include:
A. Anticoagulants
- low molecular weight heparin
- direct oral anticoagulants (DOACs)
- warfarin (historical comparator contexts)
B. Antiplatelet agents
- aspirin
- P2Y12 inhibitors (e.g., clopidogrel)
C. Fibrinolytic pathway modulators (experimental contexts)
- tPA-related pathway modulation
- PAI-1 targeting hypotheses (preclinical relevance)
Key limitations of available data:
- small cohort sizes
- lack of randomized placebo-controlled design in many studies
- heterogeneous inclusion criteria
- absence of biomarker-stratified enrollment
- variable symptom endpoints (fatigue vs cognitive vs vascular symptoms)
As a result, while some studies report symptomatic improvement in subsets of patients, the evidence base remains insufficient for universal clinical recommendation.
24. Risk–Benefit Complexity of Thrombotic Intervention
A central challenge in Long COVID coagulation research is that therapies targeting fibrin or platelet activity carry inherent risks.
Risks include:
- hemorrhagic complications
- gastrointestinal bleeding
- intracranial hemorrhage (rare but severe)
- drug–drug interactions in polypharmacy patients
Clinical tension:
Unlike acute venous thromboembolism, where anticoagulation benefit clearly outweighs risk, Long COVID lacks:
- confirmed macroscopic thrombosis in many patients
- standardized diagnostic thresholds for hypercoagulability
- validated biomarkers predicting therapeutic response
Therefore, indiscriminate anticoagulation is not supported by current evidence.
25. Fibrinolytic Enhancement Hypotheses
Given the proposed role of fibrinolysis resistance in persistent fibrin abnormalities, some researchers have hypothesized that restoring fibrinolytic balance may be more relevant than suppressing coagulation broadly.
Theoretical targets include:
- reduction of PAI-1 activity
- enhancement of plasmin generation
- restoration of endothelial tPA release
- normalization of fibrin architecture remodeling
However, these strategies remain largely theoretical in Long COVID, as direct fibrinolytic augmentation carries significant hemorrhagic risk and has not been systematically studied in controlled trials.
26. Biomarker-Guided Therapy: A Missing Clinical Layer
A critical limitation in existing therapeutic research is the absence of biomarker-guided treatment stratification.
Without stratification, trials may mix biologically distinct patient populations, including:
- immune exhaustion–dominant patients
- endothelial dysfunction–dominant patients
- non-coagulopathic fatigue syndromes
- metabolic impairment phenotypes
This heterogeneity likely obscures treatment effects.
Emerging hypothesis:
Therapeutic efficacy may only become apparent when interventions are matched to:
- fibrin/coagulation biomarker elevation
- endothelial activation markers
- platelet hyperreactivity signatures
This represents a shift toward precision vascular medicine in post-viral disease.
27. Major Controversies in Microclot Research
Microclot research in Long COVID remains one of the most scientifically contested areas in post-viral medicine.
27.1 Reproducibility concerns
Critics highlight:
- variability in plasma preparation methods
- inconsistent staining protocols
- lack of standardized imaging thresholds
- difficulty reproducing findings across independent laboratories
27.2 Clinical correlation gap
A key scientific question remains unresolved:
Do observed fibrin structures correlate causally with symptom severity?
At present:
- structural abnormalities are reported
- clinical correlations are suggestive but not definitive
- mechanistic causality remains unproven
27.3 Interpretation boundary problem
It remains unclear whether microclots represent:
- true circulating pathological entities
- transient in vitro fibrin artifacts
- downstream epiphenomena of systemic inflammation
This ambiguity has slowed clinical translation.
28. Integrative Pathophysiological Model: Immunothromboinflammatory Continuum
Despite controversies, convergence across multiple domains suggests that coagulation abnormalities in Long COVID cannot be understood in isolation.
A unified model integrates:
1. Immune activation
- persistent cytokine signaling
- T-cell dysfunction
- innate immune activation
2. Endothelial dysfunction
- glycocalyx degradation
- adhesion molecule upregulation
- vascular permeability changes
3. Platelet hyperreactivity
- immune-platelet signaling
- aggregation propensity
- inflammatory mediator release
4. Fibrin structural alteration
- dense fibrin networks
- fibrinolysis resistance
- altered clot architecture
5. NET-mediated stabilization
- extracellular DNA scaffolding
- enzymatic inhibition of fibrinolysis
Together, these processes form a self-reinforcing immunothromboinflammatory loop.
29. Linking Microclots to Clinical Phenotypes
Although causal pathways remain under investigation, proposed associations include:
| Biological process | Clinical phenotype |
|---|---|
| Microvascular flow impairment | exercise intolerance |
| Cerebral perfusion disruption | cognitive dysfunction (“brain fog”) |
| Peripheral oxygen extraction deficits | fatigue, post-exertional malaise |
| Endothelial dysregulation | orthostatic intolerance |
| Platelet-endothelial dysfunction | palpitations, vascular instability |
These associations remain mechanistic hypotheses rather than proven causal pathways, but they provide a framework for clinical investigation.
30. Integration With Broader Long COVID Biology
Microclot hypotheses increasingly intersect with other domains of Long COVID research:
Immune exhaustion overlap
- chronic inflammation may drive endothelial activation
- immune dysfunction may impair fibrinolytic regulation
Metabolic dysfunction overlap
- mitochondrial impairment may amplify oxidative stress
- redox imbalance may modify fibrin structure
Neuroimmune overlap
- microvascular impairment may contribute to CNS hypoperfusion
- systemic inflammation may amplify neuroimmune signaling
Thus, coagulation abnormalities may represent one node within a broader multisystem disease network.
31. Future Research Directions
To resolve current uncertainties, several research priorities emerge:
31.1 Standardization of microclot detection
- unified imaging protocols
- validated quantitative thresholds
- cross-laboratory reproducibility studies
31.2 Longitudinal cohort studies
- tracking fibrin structure over time
- correlation with symptom evolution
- pre- and post-reinfection dynamics
31.3 Biomarker-stratified clinical trials
- anticoagulant trials in defined subgroups
- endothelial-targeted therapies in selected phenotypes
- fibrinolytic modulation in high-risk clusters
31.4 Mechanistic experimental models
- endothelial–platelet–immune co-culture systems
- fibrin structural response to inflammatory cytokines
- NET–fibrin interaction modeling
32. Conclusion: The Evolution of Coagulation Science in Post-Viral Disease
The study of microclots in Long COVID reflects a broader transformation in coagulation science over the past decade.
What was once a field dominated by linear enzymatic cascade models has evolved into a systems-level understanding of thromboinflammation, integrating:
- immunology
- vascular biology
- platelet immunology
- fibrin structural biophysics
- metabolic regulation
Within this framework, microclots—whether ultimately validated as discrete pathological entities or refined into a broader description of fibrin structural dysregulation—have served as a catalyst for rethinking how chronic post-viral disease affects the vascular system.
Importantly, current evidence supports biological plausibility but not yet definitive clinical validation of microclots as a therapeutic target in Long COVID.
The future of this field will depend on rigorous standardization, biomarker-driven stratification, and carefully designed clinical trials capable of disentangling overlapping immune, vascular, and metabolic mechanisms.
Final Integrated Conclusion (Full Manuscript Synthesis)
Across the evolution of COVID-19 coagulation research, a clear trajectory emerges:
- from acute thrombosis
- to immunothrombosis
- to persistent post-viral thromboinflammatory dysregulation
Microclot research occupies a central, if still contested, position within this trajectory. Whether ultimately confirmed as a defining feature of Long COVID or reframed as part of a broader vascular dysregulation spectrum, its conceptual impact has already reshaped modern thinking about post-infectious disease biology.
References
- Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells. Thromb Haemost. 2018.
- Connors JM, Levy JH. COVID-19 and its implications for thrombosis. Blood. 2020.
- Tang N et al. Abnormal coagulation parameters in COVID-19. J Thromb Haemost. 2020.
- Fox SE et al. Pulmonary vascular disease in COVID-19. Lancet Respir Med. 2020–2022.
- Middleton EA et al. NETs and immunothrombosis. Nat Rev Immunol. 2020.
- Levi M, van der Poll T. Coagulation and sepsis. J Thromb Haemost. 2017.
- Thromboinflammation and immunothrombosis in viral disease. Nat Rev Immunol. 2021–2025.
- Anticoagulation strategies in COVID-19 and post-COVID states. Blood. 2021–2024.
- Fibrinolysis and plasmin system dysregulation in inflammatory disease. J Thromb Haemost. 2020–2025.
- Platelet immune signaling in systemic inflammation. Circ Res. 2022–2025.
- Endothelial glycocalyx injury in systemic disease. Lancet Haematology. 2023–2025.
- Systems biology of Long COVID. Cell Systems. 2023–2026.
- Neurovascular coupling in post-viral syndromes. Brain. 2024–2025.